Bio Green Med Solution, Inc. (BGMS)

NASDAQ: BGMS · Real-Time Price · USD
0.9650
-0.0050 (-0.52%)
At close: May 26, 2026, 4:00 PM EDT
0.9621
-0.0029 (-0.30%)
After-hours: May 26, 2026, 6:54 PM EDT
Market Cap5.33M -91.4%
Revenue (ttm)1.53M +10,792.9%
Net Income-14.23M
EPS-4.11
Shares Out 5.52M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,508
Open0.9750
Previous Close0.9700
Day's Range0.9650 - 1.0700
52-Week Range0.7303 - 29.0500
Beta-0.48
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About BGMS

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It is also involved in research and development of pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. Bio Green Med Solution, Inc. was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 12
Stock Exchange NASDAQ
Ticker Symbol BGMS
Full Company Profile

Financial Performance

In 2025, Bio Green Med Solution's revenue was $747,000, an increase of 1637.21% compared to the previous year's $43,000. Losses were -$14.09 million, 25.7% more than in 2024.

Financial Statements

News

BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety p...

12 days ago - GlobeNewsWire

Bio Green Med Solution Earnings release: Q1 2026

Bio Green Med Solution released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.

12 days ago - Filings

Bio Green Med Solution Quarterly report: Q1 2026

Bio Green Med Solution has published its Q1 2026 quarterly earnings report on May 14, 2026.

12 days ago - Filings

Bio Green Med Solution Proxy statement: Proxy filing

Bio Green Med Solution filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.

25 days ago - Filings

Bio Green Med Solution Proxy statement: Proxy filing

Bio Green Med Solution filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.

4 weeks ago - Filings

BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company e...

2 months ago - GlobeNewsWire

Bio Green Med Solution Annual report: Q4 2025

Bio Green Med Solution has published its Q4 2025 annual report on March 30, 2026.

2 months ago - Filings

Bio Green Med Solution Earnings release: Q4 2025

Bio Green Med Solution released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.

2 months ago - Filings

Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified c...

6 months ago - GlobeNewsWire

Bio Green Med Solution Quarterly report: Q3 2025

Bio Green Med Solution has published its Q3 2025 quarterly earnings report on November 13, 2025.

6 months ago - Filings

Bio Green Med Solution Earnings release: Q3 2025

Bio Green Med Solution released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.

6 months ago - Filings

Bio Green Med Solution Proxy statement: Proxy Filing

Bio Green Med Solution filed a proxy statement on August 25, 2025, providing details for shareholder voting and corporate governance matters.

9 months ago - Filings

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...

10 months ago - GlobeNewsWire

Bio Green Med Solution Quarterly report: Q2 2025

Bio Green Med Solution has published its Q2 2025 quarterly earnings report on August 13, 2025.

10 months ago - Filings

Bio Green Med Solution Earnings release: Q2 2025

Bio Green Med Solution released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.

10 months ago - Filings

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...

10 months ago - GlobeNewsWire

Bio Green Med Solution Registration statement: Registration Filing

Bio Green Med Solution filed a registration statement on July 31, 2025, providing details about a securities offering with the SEC.

10 months ago - Filings

Bio Green Med Solution Registration statement: Registration Filing

Bio Green Med Solution filed a registration statement on July 24, 2025, providing details about a securities offering with the SEC.

10 months ago - Filings

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and          occurs mostly in adolescents and young adults -

11 months ago - GlobeNewsWire

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative m...

11 months ago - GlobeNewsWire

Cyclacel Pharmaceuticals Announces Stock Split

BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative m...

11 months ago - GlobeNewsWire

Bio Green Med Solution Proxy statement: Proxy Filing

Bio Green Med Solution filed a proxy statement on June 25, 2025, providing details for shareholder voting and corporate governance matters.

11 months ago - Filings

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today a...

1 year ago - GlobeNewsWire

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovativ...

1 year ago - GlobeNewsWire

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...

1 year ago - GlobeNewsWire